Avalo Therapeutics Inc [NASDAQ: AVTX] slipped around -0.01 points on Friday, while shares priced at $0.09 at the close of the session, down -7.76%. The company report on November 9, 2023 at 7:00 AM that Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates.
Successfully eliminated $35 million debt paving the way for future growth and innovation.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Divested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assets.
Avalo Therapeutics Inc stock is now -98.21% down from its year-to-date (YTD) trading value. AVTX Stock saw the intraday high of $0.0973 and lowest of $0.087 per share. The company’s 52-week high price is 6.48, which means current price is +12.16% above from all time high which was touched on 01/18/23.
Compared to the average trading volume of 74.07M shares, AVTX reached a trading volume of 22441698 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Avalo Therapeutics Inc [AVTX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AVTX shares is $0.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AVTX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Avalo Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 24, 2021.
The Average True Range (ATR) for Avalo Therapeutics Inc is set at 0.02, with the Price to Sales ratio for AVTX stock in the period of the last 12 months amounting to 7.73. The Price to Book ratio for the last quarter was 1.18, with the Price to Cash per share for the same quarter was set at 0.05.
How has AVTX stock performed recently?
Avalo Therapeutics Inc [AVTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.49. With this latest performance, AVTX shares dropped by -39.29% in over the last four-week period, additionally sinking by -96.33% over the last 6 months – not to mention a drop of -98.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVTX stock in for the last two-week period is set at 38.29, with the RSI for the last a single of trading hit 34.16, and the three-weeks RSI is set at 39.02 for Avalo Therapeutics Inc [AVTX]. The present Moving Average for the last 50 days of trading for this stock 0.1255, while it was recorded at 0.1007 for the last single week of trading, and 1.5622 for the last 200 days.
Avalo Therapeutics Inc [AVTX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Avalo Therapeutics Inc [AVTX] shares currently have an operating margin of -207.41 and a Gross Margin at +80.77. Avalo Therapeutics Inc’s Net Margin is presently recorded at -230.78.
Return on Total Capital for AVTX is now -102.35, given the latest momentum, and Return on Invested Capital for the company is -125.83. Return on Equity for this stock declined to -684.77, with Return on Assets sitting at -73.35. Additionally, AVTX Total Debt to Total Capital is recorded at 185.65, with Total Debt to Total Assets ending up at 70.91.
Reflecting on the efficiency of the workforce at the company, Avalo Therapeutics Inc [AVTX] managed to generate an average of -$2,082,900 per employee. Receivables Turnover for the company is 5.37 with a Total Asset Turnover recorded at a value of 0.32.Avalo Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.11 and a Current Ratio set at 2.11.
Insider trade positions for Avalo Therapeutics Inc [AVTX]
The top three institutional holders of AVTX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in AVTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in AVTX stock with ownership which is approximately 5.7994%.
